"We fully expect remdesivir to be effective against these new strains," Gilead Sciences CEO Daniel O'Day told CNBC. Gilead hiked its 2020 guidance due in part to a surge in demand for remdesivir ...

Gilead Sciences announced the pending departure of chief medical officer Merdad Parsey, MD, PhD on Wednesday morning. Parsey will remain in his role until Q1 2025 and lend support to the company as it ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Gilead Sciences chief Daniel O ...

Daniel O’Day and a group of Gilead employees visited with San Francisco Community Health Center staff last fall. Image courtesy of San Francisco Business Times. Originally published by SAN FRANCISCO ...

Gilead Sciences’ CEO John Milligan, PhD, will step down from his role by the end of the year, the Wall Street Journal reported. 1. Dr. Milligan will also step down from the board of directors once his ...

The MarketWatch News Department was not involved in the creation of this content. Groups welcome reversal of Gilead's price gouging decision that would have resulted in fewer people with HIV getting ...

Gilead Sciences announced Monday morning it will acquire biotech CymaBay Therapeutics in a deal worth $4.3 billion. The acquisition gives Gilead rights to CymaBay’s lead candidate — a drug called ...

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday. The positive phase-three trial data on lenacapavir sets the stage for likely approval by ...

We're not making any changes to our $86 per share fair value estimate for Gilead's 2018 was a year of massive management turnover, and while we think the hiring of O'Day adds stability, we're ...